Leukotrienes and atherosclerosis

Indian Heart Journal

Volumn 57, Issue 2, 2005, Pages 175-180

  Khan, Zeba ^a   Tripathi, C D ^a  

^a SAFDARJUNG HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 (4 BIPHENYLYLMETHYL) 4 HYDROXYCHROMAN 7 YL]CYCLOPENTANECARBOXYLIC ACID; DG 031; GSK 480848; LEUKOTRIENE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BIOSYNTHESIS; CELL PROLIFERATION; CHEMOTAXIS; ENDOTHELIUM CELL; FATTY ACID OXIDATION; HUMAN; LIPOPROTEIN METABOLISM; MONOCYTE; REVIEW;

CORONARY ARTERIOSCLEROSIS; HUMANS; LEUKOTRIENES;

EID: 22244459161     PISSN: 00194832     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Steinberg D. Atherogenesis in perspective: hypercholestrolemia and inflammation as partners in crime. Nat Med 2002; 8: 1211-1217
2. Badimon JJ, Fuster V, Chesebro JH, Badimon L. Coronary atherosclerosis: a multifactorial disease. Circulation 1993; 87 (Suppl 2): II3-II16
3. Brash AR. Lipoxygenases: occurrence, function, catalysis and acquisition of substrate. J Biol Chem 1999; 274: 23679-23682
4. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871-1875
5. Radmark O. Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat 2002; 68-69: 211-234
6. Radmark O. 5-lipoxygenase-derived leukotrienes, mediators also of atherosclerotic inflammation. Arterioscler Thromb Vasc Biol 2003; 23: 1140-1142
7. Morrow JD, Roberts LJ 2nd. In: Joel G Hardman, Lee Elimbird (eds). Lipid-derived Autacoids: Eicosanoids and platelet Activating Factor. Goodman & Gillman's the Pharmacological Basis of Therapeutics. McGraw Hill, 10 ed. 2001; pp 669-685
8. Allen SP, Yacoub MH. Role of leukotrienes in coronary artery surgery. Curr Opin Cardiol 1995; 10: 605-613
9. Evans JF. Cysteinyl leukotrienes receptors. Prostaglandins Other Lipid Mediat 2002; 68-69: 587-597
10. 4 that mediates chemotaxis. Nature 1997; 387: 620-624
11. 4 receptor BLT2. A new therapeutic target in inflammation and immunological disorder. J Exp Med 2000; 192: 421-431
12. 4 receptors in the development of atherosclerosis: potential mechanisms. Arteriosder Thromb Vasc Biol 2004; 24: 369-375
13. 4 pathway to inflammation control. Nature 1996; 384: 39-43
14. 4 plays a critical role in the progression of collagen-induced arthritis. Proc Natl Acad Sci USA 1995; 92: 517-521
15. Brink C, Dahlen SE, Drazen J, Evans JF, Hay DW, Nicosia S, et al. International Union of Pharmacology 37th. Nomenclature for leukotrienes and lipoxin receptors. Pharmacol Rev 2003; 55: 195-227
16. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposh W, et al. Identification of 5-Lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002; 91: 120-126
17. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA 2003; 100: 1238-1243
18. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid and atherosclerosis. N Engl J Med 2004; 350: 29-37
19. Harats D, Shaish A, George J, Mulkins M, Kurihara H, Le et al. Overexpression of 15-lipoxygenase in vascular endothelium accelerates early atherosclerosis in LDL receptor deficient mice. Arterioscler Thromb Vasc Biol 2000; 20: 2100-2105
20. Allen S, Dashwood M, Morrison K, Yacoub M. Differential leukotrienes constrictor responses in human atherosclerotic coronary arteries. Circulation 1998; 97: 2406-2413
21. 4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 2002; 22: 443-449
22. 4. J Immunol 1999; 163: 6148-6154
23. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff MF, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 2000; 105: 1049-1056
24. 4 induced IL-1β expression and release in rat vascular smooth muscle cells. Atherosclerosis 1995; 115: 181-189
25. Caterina DR, Zampolli A. From asthma to atherosclerosis-5-lipoxygenase, leukotrienes and inflammation. N Engl J Med 2004; 350: 4-7
26. Fair A, Pritchard KAJ. Oxidized low-density lipoprotein increases U937 cell lipoxygenase activity; induction of 5-lipoxygenase activating protein. Biochem Biophys Res Commun 1994; 201: 1014-1020
27. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004; 36: 233-239
28. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemo-attractant protein-1 reduces atherosclerosis in low-density lipo-protein receptor deficient mice. Mol Cell 1998; 2: 275-281
29. -/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 1998; 394: 894-897
30. 4 stimulate human endothelial cells to synthesize platelet activating factor and bind neutrophils. Proc Natl Acad Sci USA 1986; 83: 2204-2208